Stander S, Zeidler C, Pereira M, Szepietowski JC, McLeod L, Qin S, Williams N, Sciascia T, Augustin M. Worst itch numerical rating scale for Prurigo Nodularis: a psychometric evaluation. J Eur Acad Dermatol Venereol. 2022 Apr;36(4):573-81. doi: 10.1111/jdv.17870
Chen YH, Farnham PG, Hicks KA, Sansom SL. Estimating the HIV effective reproduction number in the United States and evaluating HIV elimination strategies. J Public Health Manag Pract. 2022 Mar;28(2). doi: 10.1097/PHH.0000000000001397
Lewis JH, Whelihan K, Roy D, White EJ, Morgan C, Vora RS, Boyle KR, Luebbering C, Bay RC, Lindley MC. Vaccination capability inventory of community, migrant, and homeless health centers: a survey report. J Public Health Manag Pract. 2020 Mar;26(2):139-47. doi: 10.1097/PHH.0000000000001073
Augustin M, McBride D, Gilloteau I, O'Neill C, Neidhardt K, Graham CN. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2191-9. doi: 10.1111/jdv.15047
Warren RB, Halliday A, Graham CN, Gilloteau I, Miles L, McBride D. Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2178-84. doi: 10.1111/jdv.15094
Jacobson EU, Hicks KA, Tucker EL, Farnham PG, Sansom SL. Effects of reaching national goals on HIV incidence, by race and ethnicity, in the United States. J Public Health Manag Pract. 2018 Jul;24(4):E1-8. doi: 10.1097/PHH.0000000000000717
Augustin M, Abeysinghe S, Mallya U, Qureshi A, Roskell N, McBride D, Papavassillis C, Gelfand J. Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial. J Eur Acad Dermatol Venereol. 2016 Apr;30(4):645-9. doi: 10.1111/jdv.13478
Candrilli SD, Meyers JL, Boye K, Bae JP. Health care resource utilization and costs during episodes of care for type 2 diabetes mellitus-related comorbidities. J Diabetes Complications. 2015 May;29(4):529-33. doi: 10.1016/j.jdiacomp.2014.12.009
Cilenti D, Kum HC, Wells R, Whitmire JT, Goyal RK, Hillemeier MM. Changes in North Carolina maternal health service use and outcomes among medicaid-enrolled pregnant women during state budget cuts. J Public Health Manag Pract. 2015 Mar;21(2):208-13. doi: 10.1097/PHH.0000000000000118
Cho BH, Hicks KA, Honeycutt AA, Hupert N, Khavjou O, Messonnier M, Washington ML. A Tool for the Economic Analysis of Mass Prophylaxis Operations With an Application to H1N1 Influenza Vaccination Clinics. J Public Health Manag Pract. 2011 Jan 1;17(1):E22-8.
Candrilli SD, Davis KL, Kan HJ, Lucero MA, Rousculp MD. Prevalence and the associated burden of illness of symptoms of diabetic peripheral neuropathy and diabetic retinopathy. J Diabetes Complications. 2007 Oct 1;21(5):306-14.
McKennas SP, Whalley D, deProst Y, Staab D, Huels J, Paul CF, vanAssche D. Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life. J Eur Acad Dermatol Venereol. 2006 Mar 1;20(3):248-54.
Doward LC, McKenna SP, Whalley D, Tennant A, Griffiths B, Emery P. Measuring quality of life in lupus: development of the SLEQoL. Poster presented at the First EADV International Spring Symposium; February 2003. [abstract] J Eur Acad Dermatol Venereol. 2003 Mar; 17(Suppl 1):58.